The Court of Appeal in Paris has ruled that Sanofi must pay 150.7 million euros to CNAM as compensation for anti-competitive practices related to the drug Plavix.
Matei Gaginsky
International
Foto: Sylvain ROBIN / Alamy / Profimedia
Always see our news on Google
The court's decision is based on a ruling from 2013, when Sanofi was fined 40.6 million euros for actions against generic drug manufacturers. The court found that the impact of these practices persisted until 2021, although the anti-competitive behavior lasted only five months. CNAM will receive 126.2 million euros for reimbursements and fees, plus 24.5 million euros in damages. Sanofi is reviewing the ruling and considers the possibility of an appeal to the Supreme Court.
Sources
Latest News
23:52
Sorin Grindeanu, on the appointment of Siegfried Mureșan as prime minister: “He will go down gloriously in Parliament”
23:37
Nicușor Dan is said to have proposed Siegfried Mureșan for the position of prime minister without informing the coalition leaders beforehand (sources)
23:22
Dominic Fritz denies having told Nicușor Dan: “This thing with Romania is your problem; the party is my problem”
23:16
Donald Trump withdrew his proposal to lead ICE
22:53
Mark Carney Rejects U.S. Pressure and Backs Closer Ties Between Canada and the EU
See more news
NEWS ON THE SAME TOPICS
International
Germany will provide €400 million to maintain Sanofi’s insulin production and reduce the risk of shortages in Europe
International
Poland contests the ruling of the Brussels Tribunal to pay 1.3 billion euros for the Pfizer vaccines
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
